var data={"title":"Streptomycin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Streptomycin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6988?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">see &quot;Streptomycin: Drug information&quot;</a> and <a href=\"topic.htm?path=streptomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Streptomycin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709418\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The risk of severe neurotoxic reactions is sharply increased in patients with impaired renal function or prerenal azotemia. These include disturbances of vestibular and cochlear function, optic nerve dysfunction, peripheral neuritis, arachnoiditis, and encephalopathy. The incidence of clinically detectable, irreversible vestibular damage is particularly high in patients treated with streptomycin.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal function should be monitored carefully; patients with renal impairment and/or nitrogen retention should receive reduced doses. The peak serum concentration in individuals with kidney damage should not exceed 20 to 25 mcg/mL.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concurrent or sequential use of other neurotoxic and/or nephrotoxic drugs with streptomycin, including neomycin, kanamycin, gentamicin, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, tobramycin, and cyclosporine should be avoided.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The neurotoxicity of streptomycin can result in respiratory paralysis from neuromuscular blockage, especially when the drug is given soon after the use of anesthesia or muscle relaxants.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The administration of streptomycin in parenteral form should be reserved for patients where adequate laboratory and audiometric testing facilities are available during therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14595275\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Streptomycin for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049985\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Aminoglycoside</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antitubercular Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445115\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Tuberculosis; multidrug-resistant (MDR):</b> Limited data available: <b>Note:</b> Streptomycin is not recommended for initial treatment of tuberculosis and should be reserved for use as part of multidrug-resistant (MDR) TB regimens; usefulness limited by high rates of resistance (Blumberg 2003; WHO 2010); monitor plasma concentrations: IM, IV: <b>Note:</b> IM route preferred; consider use of IV route if IM therapy not tolerated (Bradley 2015; Morris 1994; P&eacute;rez Tanoira 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Daily therapy:</i> 20 to 40 mg/kg/day (Abughali 1994; Cantwell 1994; Okascharoen 2003; Skevaki 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Twice weekly:</i> 20 to 40 mg/kg/dose twice weekly (Skevaki 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049978\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">see &quot;Streptomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> IM route preferred; consider use of IV route if IM therapy not tolerated. Monitor serum drug concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, combination therapy for susceptible infection:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IM: 20 to 40 mg/kg/day in divided doses every 6 to 12 hours; maximum dose: 1,000 mg/dose; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IM, IV: 20 to 30 mg/kg/day divided every 12 hours; maximum daily dose: 1,000 mg/<b>day</b> (Bradley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, <i>Enterococcal</i>, resistant to gentamicin:</b> Infants, Children, and Adolescents: IM, IV: 20 to 30 mg/kg/day divided every 12 hours; maximum daily dose: 2,000 mg/<b>day</b>; used in combination with other antibiotics, adjust dose to target concentrations (AHA [Baddour] 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium avium</i> complex, treatment:</b> Limited data available: Adolescents: IM, IV: 1,000 mg once daily as part of combination therapy (HHS [Adult] 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium ulcerans</i> (Buruli ulcers):</b> Limited data available: Infants, Children, and Adolescents: IM: 15 mg/kg once daily; maximum daily dose: 1,000 mg/day; used in combination with rifampin for 8 weeks, or may use this combination for 4 weeks, followed by 4 weeks of rifampin-claithromycin combination therapy (WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plague:</b> Infants, Children, and Adolescents: IM, IV: 30 mg/kg/day divided every 12 hours for 10 days; maximum daily dose: 2,000 mg/<b>day</b> <i>(Red Book</i> [AAP] 2015; WHO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tuberculosis; active infection; treatment (second-line therapy); multidrug-resistant (MDR) or meningitis: Note: </b>Always use as part of a multidrug regimen. Any regimens using less than once daily dosing should administer dosing as directly observed therapy (DOT). Treatment regimens for MDR TB are variable depending upon sensitivity and clinical response. Streptomycin frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines for detailed information (ATS/CDC/IDSA [Nahid 2016]; Schaaf 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary pulmonary disease:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Once daily therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years weighing &le;40 kg: <b>Note:</b> Suggested expert dosing range is large and variable (Schaaf 2015); IM, IV: 15 to 40 mg/kg/dose once daily; some experts recommend an initial dose range of 15 to 20 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b>; monitor serum concentrations (ATS/CDC/IDSA [Nahid 2016]; Schaaf 2015; WHO, 2009a). <b>Note:</b> Some clinicians suggest every 12-hour dosing may be utilized (Berenberg 1951; Bradley 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: IM, IV: 15 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b>; monitor serum concentrations (ATS/CDC/IDSA [Nahid 2016]; P&eacute;rez Tanoira 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Three-times-weekly DOT: </i>Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: IM, IV: 25 mg/kg/dose three times weekly; maximum dose: 1,000 mg/dose (ATS/CDC/IDSA [Nahid 2016]</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Twice weekly DOT:</i> Infants, Children, and Adolescents &lt;15 years weighing &le;40 kg: IM, IV: 25 to 30 mg/kg/dose twice weekly; maximum dose: 1,000 mg/dose (ATS/CDC/IDSA [Nahid 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis (independent of HIV-status): Infants, Children, and Adolescents: <b>Note:</b> Suggested expert dosing range is large and variable (Schaaf 2015): IM, IV: 15 to 40 mg/kg/dose once daily; some experts recommend an initial dose range of 15 to 20 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b>; monitor serum concentrations (ATS/CDC/IDSA [Nahid 2016]; DHHS [pediatric] 2013; <i>Red Book</i> [AAP] 2015; Schaaf 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tularemia:</b> Infants, Children, and Adolescents: IM: 15 mg/kg/dose twice daily for 10 days; maximum daily dose: 2,000 mg/<b>day</b> (WHO 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dosage range:</b> IM: 15 to 30 mg/kg/day or 1,000 to 2,000 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Endocarditis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Enterococcal:</i> IM: 1,000 mg every 12 hours for 2 weeks, then 500 mg every 12 hours for 4 weeks in combination with penicillin</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Streptococcal:</i> IM: 1,000 mg every 12 hours for 1 week, then 500 mg every 12 hours for 1 week in combination with penicillin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Plague:</b> IM: 30 mg/kg/day (or 2,000 mg) divided every 12 hours until the patient is afebrile for at least 3 days.<b> Note:</b> Full course is considered 10 days (WHO 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Tuberculosis:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Daily therapy:</i> 15 mg/kg/day once daily (maximum dose: 1,000 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Directly observed therapy (DOT), twice weekly:</i> 25 to 30 mg/kg/dose twice weekly (maximum dose: 1,500 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Directly observed therapy (DOT), 3-times-weekly:</i> 25 to 30 mg/kg 3-times-weekly (maximum dose: 1,500 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Tularemia:</b> IM: 1,000 to 2,000 mg daily in divided doses every 12 hours (maximum daily dose: 2,000 mg/day) for 7 to 14 days until patient is afebrile for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: <b>Note:</b> Renally adjusted dose recommendations are based on doses of 20 to 40 mg/kg/day every 24 hours. Monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 7.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 7.5 mg/kg/dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 7.5 mg/kg/dose every 72 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD): Administer 7.5 mg/kg/dose every 72 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): Administer 7.5 mg/kg/dose every 72 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer every 24 hours; monitor levels. <b>Note:</b> Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aronoff 2007: <b>Note:</b> Recommendations are based on doses of 1 to 2 g every 6 to 12 hours (1 g once daily for tuberculosis):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute: Administer every 24 to 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer every 72 to 96 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">End-stage renal disease (ESRD):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Intermittent hemodialysis (IHD): One-half the recommended dose administered after hemodialysis on dialysis days. <b>Note:</b> Dosing dependent on the assumption of 3-times-weekly complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis (PD): Administration via PD fluid: 20 to 40 mg/L (20 to 40 mcg/mL) of PD fluid</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer every 24 to 72 hours; monitor levels. <b>Note:</b> Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ATS 2003:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tuberculosis:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;30 mL/minute: 12 to 15 mg/kg/dose (maximum dose: 1,000 mg) 2 to 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): 12 to 15 mg/kg/dose (maximum dose: 1,000 mg) 2 to 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223184\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223168\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049990\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Inject deep IM into a large muscle mass; rotate injection sites  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: After further dilution, infuse over 30 to 60 minutes (Morris 1994; Peloquin 1992; P&eacute;rez Tanoira 2014) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223200\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Reconstituted solution may be stored at room temperature for up to 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Depending upon manufacturer, reconstituted solution remains stable for 24 hours at room temperature. Exposure to light causes darkening of solution without apparent loss of potency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049989\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Combination therapy for active tuberculosis (FDA approved in pediatric patients [age not specified] and adults); combination therapy with other agents for treatment of bacteremia caused by susceptible gram-negative bacilli, brucellosis, chancroid, granuloma inguinale, <i>H. influenzae</i> (respiratory, endocardial, meningeal infections), <i>K. pneumoniae</i>, plague, streptococcal or enterococcal endocarditis, tularemia, urinary tract infections (caused by <i>A. aerogenes</i>, <i>E. coli</i>, <i>E. faecalis</i>, <i>K. pneumoniae</i>, <i>Proteus spp</i>)   (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223230\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Streptomycin may be confused with streptozocin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223227\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drug fever, facial paresthesia, headache, neurotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Exfoliative dermatitis, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azotemia, nephrotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory ototoxicity, vestibular ototoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223192\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to streptomycin, other aminoglycosides, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223172\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular blockade and respiratory paralysis:<b> [US Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis; especially when given soon after anesthesia or muscle relaxants.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity, including disturbances of vestibular and cochlear function, optic nerve dysfunction, peripheral neuritis, arachnoiditis, and encephalopathy; </b>usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Baseline and periodic caloric stimulation and audiometric tests are recommended with prolonged therapy. Discontinue treatment if signs of ototoxicity occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hearing impairment: Use with caution in patients with pre-existing vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: <b> [US Boxed Warning]:  May cause nephrotoxicity.</b> Use with caution in patients with renal impairment; dose adjustment necessary in patients with renal impairment and/or nitrogen retention. Monitor renal function closely; peak serum concentrations should not surpass 20 to 25 mcg/mL in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;  Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxic and/or nephrotoxic drugs:<b> [US Boxed Warning]: Avoid concomitant or sequential use with other neurotoxic and/or nephrotoxic drugs (eg, neomycin, kanamycin, gentamicin, paromomycin, polymyxin B, colistin, tobramycin, cyclosporine).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfite sensitivity: Some formulations may contain sodium metabisulfite; may cause allergic reactions including anaphylaxis or asthma exacerbations (some life-threatening) in susceptible patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use:<b> [US Boxed Warning]: Parenteral form should be used only where appropriate audiometric and laboratory testing facilities are available.</b> IM injections should be administered in a large muscle well within the body to avoid peripheral nerve damage and local skin reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300082\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223177\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12807&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): Streptomycin may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223180\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5722065\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Streptomycin crosses the placenta. Streptomycin may cause fetal harm if administered to a pregnant woman. There are multiple reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Streptomycin should never be substituted as first line therapy for the treatment of tuberculosis in pregnant women (Blumberg 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049984\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Audiometric measurements and vestibular function (baseline, periodically while on therapy following discontinuation of therapy); renal function (baseline, periodically while on therapy and following discontinuation of therapy); baseline and frequent assessment of serum electrolytes (including calcium, magnesium, and potassium), liver function tests, growth parameters (CDC 2003; Seddon 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049988\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic: Peak: 20 to 30 mcg/mL; Trough: &lt;5 mcg/mL; Toxic: Peak: &gt;50 mcg/mL; Trough: &gt;10 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tuberculosis treatment: Pediatric patients: Although exact pharmacokinetic/dynamic aminoglycoside targets are unknown for <i>M. Tuberculosis</i>; experts suggest peak values (Cmax): 35 to 45 mcg/mL for once daily therapy; and for twice weekly: 65 to 80 mcg/mL (Schaaf 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223171\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial protein synthesis by binding directly to the 30S ribosomal subunits causing faulty peptide sequence to form in the protein chain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223191\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poorly absorbed; IM: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes into most body tissues and fluids except the brain; small amounts enter the CSF only with inflamed meninges </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 34% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Newborns: 4 to 10 hours; Adults: ~2 to 4.7 hours; prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM: Within 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (29% to 89% as unchanged drug); small amount (1%) excreted in bile, saliva, sweat, and tears</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323892\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Streptomycin Sulfate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $93.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223194\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ambistryn-S (IN);</li>\n      <li>Estrepto-Monaxin (MX);</li>\n      <li>Estreptomicina (AR);</li>\n      <li>Strepiovit (LK);</li>\n      <li>Strepto (TH);</li>\n      <li>Strepto-Hefa (DE);</li>\n      <li>Streptocin (MY);</li>\n      <li>Streptomycinum (PL);</li>\n      <li>Streptosol (ZW);</li>\n      <li>Stretopen (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abughali N, Van der Kuyp F, Annable W, Kumar ML. Congenital tuberculosis. <i>Pediatr Infect Dis J</i>. 1994;13(8):738-741.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/7970976 /pubmed\" target=\"_blank\" id=\"7970976 \">7970976 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo; <i>Clin Infect Dis</i>, 1995, 21:9-27.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo; <i>Pediatrics</i> 1992, 89(1):161-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/1728006/pubmed\" target=\"_blank\" id=\"1728006\">1728006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thyroid Society/Centers for Disease Control and Prevention/Infectious Disease Society of America (ATS/CDC/IDSA). Treatment of Tuberculosis. <i>Am J Respir Crit Care Med</i>. 2003. 167:603-662.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arguedas AG and Wehrle PP, &ldquo;New Concepts for Antimicrobial Use in Central Nervous System Infections,&rdquo; <i>Semin Pediatr Infect Dis</i>, 1991, 2(1):36-42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. <i>Circulation</i>. 2005;111(23):e394-434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/15956145 /pubmed\" target=\"_blank\" id=\"15956145 \">15956145 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berenberg W, Cook CD, Twinam CW. Streptomycin in pulmonary tuberculosis in children.<i> J Am Med Assoc</i>. 1951;145(14):1044-1048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/14803304 /pubmed\" target=\"_blank\" id=\"14803304 \">14803304 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumberg HM, Burman WJ, Chaisson RE, et al, &ldquo;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&rdquo; <i>Am J Respir Crit Care Med</i>, 2003, 167(4):603-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/12588714/pubmed\" target=\"_blank\" id=\"12588714\">12588714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 21st ed. American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cantwell MF, Shehab ZM, Costello AM, et al. Brief report: congenital tuberculosis.<i> N Engl J Med</i>. 1994;330(15):1051-1054.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/8127333 /pubmed\" target=\"_blank\" id=\"8127333 \">8127333 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2016. Available at <a href=\"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorin MI, Hsu KH, and Jacob SC, &ldquo;Treatment of Tuberculosis in Children,&rdquo; <i>Pediatr Clin North Am</i>, 1983, 30(2):333-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/6602321/pubmed\" target=\"_blank\" id=\"6602321\">6602321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morris JT and Cooper RH, &ldquo;Intravenous Streptomycin: A Useful Route of Administration,&rdquo; <i>Clin Infect Dis</i>, 1994, 19(6):1150-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/7888550/pubmed\" target=\"_blank\" id=\"7888550\">7888550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okascharoen C, Nuntnarumit P, Sirinavin S. Neonatal tuberculosis associated with shock, disseminated intravascular coagulation, hemophagocytic syndrome, and hypercalcemia: a case report. <i>J Perinatol</i>. 2003;23(1):79-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/12556935 /pubmed\" target=\"_blank\" id=\"12556935 \">12556935 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peloquin CA. Shortages of antimycobacterial drugs. <i>N Engl J Med</i>. 1992;326(10):714.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/1736124 /pubmed\" target=\"_blank\" id=\"1736124 \">1736124 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Tanoira R, S&aacute;nchez-Pat&aacute;n F, Jim&eacute;nez Gir&oacute;n A, Fern&aacute;ndez Roblas R, Esteban J, Fern&aacute;ndez Guerrero ML. Tolerance and safety of intravenous streptomycin therapy in patients with tuberculosis. <i>Infection</i>. 2014;42(3):597-598.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/24748409 /pubmed\" target=\"_blank\" id=\"24748409 \">24748409 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaaf HS, Garcia-Prats AJ, Donald PR. Antituberculosis drugs in children. <i>Clin Pharmacol Ther</i>. 2015;98(3):252-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/26095192/pubmed\" target=\"_blank\" id=\"26095192\">26095192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. <i>Am J Respir Crit Care Med</i>. 2012;186(10):953-964.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/22983960 /pubmed\" target=\"_blank\" id=\"22983960 \">22983960 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skevaki CL, Kafetzis DA. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.<i> Paediatr Drugs</i>. 2005;7(4):219-234.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/streptomycin-pediatric-drug-information/abstract-text/16117559 /pubmed\" target=\"_blank\" id=\"16117559 \">16117559 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Management of MDR-TB: a &#64257;eld guide: a companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI). 2009a. Available at http://whqlibdoc.who.int/publications/2009/9789241547765_eng.pdf?ua=1. Last accessed June 2, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Operational guidelines on plague surveillance, diagnosis, prevention and control. 2009. Available at http://apps.searo.who.int/PDS_DOCS/B4534.pdf?ua=1. Last accessed May 12, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Rapid advice: treatment of tuberculosis in children. 2010. Available at http://apps.who.int/iris/bitstream/10665/44444/1/9789241500449_eng.pdf. Last accessed June 2, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Treatment of Mycobacterium ulcerans disease (Bruruli ulcer): guidance for health workers. 2012. Available at http://apps.who.int/iris/bitstream/10665/77771/1/9789241503402_eng.pdf. Last accessed May 13, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). WHO guidelines on tularemia. 2007. Available at http://whqlibdoc.who.int/publications/2007/9789241547376_eng.pdf. Last accessed May 12, 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12807 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709418\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14595275\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049985\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445115\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049978\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223184\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F223168\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049990\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F223200\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049989\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F223230\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223227\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223192\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223172\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300082\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F223177\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F223180\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5722065\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049984\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1049988\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223171\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F223191\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323892\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F223194\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12807|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=streptomycin-drug-information\" class=\"drug drug_general\">Streptomycin: Drug information</a></li><li><a href=\"topic.htm?path=streptomycin-patient-drug-information\" class=\"drug drug_patient\">Streptomycin: Patient drug information</a></li></ul></div></div>","javascript":null}